UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Preclinical evaluation of the dual specific Src/Abl kinase inhibitor AZD0530 in lung cancer

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.13108-13108

2006

Volltextzugriff (PDF)

HER-2/neu is overexpressed infrequently in patients with prostate carcinoma: Results from the california cancer consortium screening trial

Cancer, 2002-05, Vol.94 (10), p.2584-2589

2002

Volltextzugriff (PDF)

In situ study of structural modifications in Ni-Fe/MgAl2O4 catalysts employed for ethanol steam reforming

Fuel (Guildford), 2024-10, Vol.373, p.132336, Article 132336

2024

Volltextzugriff (PDF)

Bone biomarkers and overall survival (OS) in men with castrate resistant prostate cancer (CRPC) and skeletal metastases: Updated results from SWOG 0421, a phase III trial of docetaxel +/- atrasentan

Annals of oncology, 2016-10, Vol.27, p.vi256-vi256

2016

Volltextzugriff (PDF)

801PBone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) +/- orteronel

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Safety and activity of the pan–fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma

Annals of oncology, 2016-10, Vol.27, p.vi269-vi269

2016

Volltextzugriff (PDF)

912PDResults of the phase II TRAXAR study: A randomized phase II trial of axitinib and TRC105 (TRAX) versus axitinib (AX) alone in patients with advanced or metastatic renal cell carcinoma (mRCC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

LBA50Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Evaluation of Prostate-Specific Antigen Declines for Surrogacy in Patients Treated on SWOG 99-16

JNCI : Journal of the National Cancer Institute, 2006-04, Vol.98 (8), p.516-521

2006

Volltextzugriff (PDF)

Phase II trial of edatrexate in relapsed or refractory germ cell tumors : A Southwest Oncology Group Study (SWOG 9124)

Investigational new drugs, 1998, Vol.16 (4), p.347-351

1998

Volltextzugriff (PDF)

Ixabepilone (Epothilone B Analogue BMS-247550) Is Active in Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer: A Southwest Oncology Group Trial S0111

Journal of clinical oncology, 2005-12, Vol.23 (34), p.8724-8729

2005

Volltextzugriff (PDF)

Molecular–clinical correlative studies in non-small cell lung cancer: application of a three-tiered approach

Lung cancer, 2001-12, Vol.34, p.75-80

2001

Volltextzugriff (PDF)

Management and repair strategies for abdominal perforations during abdominoplasty innovative techniques and clinical outcomes: a systematic review

International journal of research in medical sciences, 2024-07, Vol.12 (8), p.2962-2968

2024

Volltextzugriff (PDF)

The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and Molecular Correlative Trial

Clinical cancer research, 2005-06, Vol.11 (12), p.4444-4450

2005

Volltextzugriff (PDF)

Phase III Trial of Paclitaxel Plus Carboplatin With or Without Tirapazamine in Advanced Non–Small-Cell Lung Cancer: Southwest Oncology Group Trial S0003

Journal of clinical oncology, 2005-12, Vol.23 (36), p.9097-9104

2005

Volltextzugriff (PDF)

Evaluation of Factors Affecting Awareness of and Willingness to Participate in Cancer Clinical Trials

Journal of clinical oncology, 2005-12, Vol.23 (36), p.9282-9289

2005

Volltextzugriff (PDF)

Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II california cancer consortium trial

Cancer chemotherapy and pharmacology, 2001-07, Vol.48 (1), p.22-28

2001

Volltextzugriff (PDF)

Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors

Anti-cancer drugs, 2013-07, Vol.24 (6), p.636-640

2013

Volltextzugriff (PDF)

Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma: A phase I/II trial of gemcitabine, paclitaxel, and methotrexate

Cancer, 2004, Vol.100 (1), p.82-88

2004

Volltextzugriff (PDF)

A Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone-Refractory Prostate Cancer Patients with Bone Metastases

Clinical cancer research, 2006-03, Vol.12 (5), p.1556-1563

2006

Volltextzugriff (PDF)

Gemcitabine/carboplatin combination regimens: importance of dose schedule

Oncology (Williston Park, N.Y.), 2000-07, Vol.14 (7 Suppl 4), p.26

2000

Volltextzugriff (PDF)

The hazards of randomized phase II trials

Annals of oncology, 2012-01, Vol.23 (1), p.7

2012

Volltextzugriff (PDF)

Integration of new chemotherapeutic agents into chemoradiotherapy for stage III non-small cell lung cancer: Focus on docetaxel

Seminars in oncology, 2001-06, Vol.28 (3), p.26-32

2001

Volltextzugriff (PDF)

Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?

Cancer, 2002-09, Vol.95 (5), p.1009-1015

2002

Volltextzugriff (PDF)

26 – 50 von 2.207

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.016)
Mit Volltextzugriff
(1.997)

Publikationsform

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(7)
... seit 90 Tagen
(31)

Menü

Weitere Dienste

Einstellungen

Preclinical evaluation of the dual specific Src/Abl kinase inhibitor AZD0530 in lung cancer

HER-2/neu is overexpressed infrequently in patients with prostate carcinoma: Results from the california cancer consortium screening trial

In situ study of structural modifications in Ni-Fe/MgAl2O4 catalysts employed for ethanol steam reforming

Bone biomarkers and overall survival (OS) in men with castrate resistant prostate cancer (CRPC) and skeletal metastases: Updated results from SWOG 0421, a phase III trial of docetaxel +/- atrasentan

801PBone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) +/- orteronel

Safety and activity of the pan–fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma

912PDResults of the phase II TRAXAR study: A randomized phase II trial of axitinib and TRC105 (TRAX) versus axitinib (AX) alone in patients with advanced or metastatic renal cell carcinoma (mRCC)

LBA50Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)

Evaluation of Prostate-Specific Antigen Declines for Surrogacy in Patients Treated on SWOG 99-16

Phase II trial of edatrexate in relapsed or refractory germ cell tumors : A Southwest Oncology Group Study (SWOG 9124)

Ixabepilone (Epothilone B Analogue BMS-247550) Is Active in Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer: A Southwest Oncology Group Trial S0111

Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial

Molecular–clinical correlative studies in non-small cell lung cancer: application of a three-tiered approach

Management and repair strategies for abdominal perforations during abdominoplasty innovative techniques and clinical outcomes: a systematic review

The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and Molecular Correlative Trial

Phase III Trial of Paclitaxel Plus Carboplatin With or Without Tirapazamine in Advanced Non–Small-Cell Lung Cancer: Southwest Oncology Group Trial S0003

Evaluation of Factors Affecting Awareness of and Willingness to Participate in Cancer Clinical Trials

Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II california cancer consortium trial

Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors

Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma: A phase I/II trial of gemcitabine, paclitaxel, and methotrexate

A Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone-Refractory Prostate Cancer Patients with Bone Metastases

Gemcitabine/carboplatin combination regimens: importance of dose schedule

The hazards of randomized phase II trials

Integration of new chemotherapeutic agents into chemoradiotherapy for stage III non-small cell lung cancer: Focus on docetaxel

Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?

Suchergebnisse filtern